Table 5.

Correlation and Univariable Mixed Effects Regression Analysis for Vancomycin Clearance^a.

Covariate	Pearson’s Coefficientb	Estimate	95% Confidence Interval	P-value
Study Groupc	-	18.0	3.5 to 32.6	0.016
Age Group, yr	0.178d	-	-	0.6 (overall)
1 to < 2	-	14.2	−33.4 to 61.8	0.5
2 to <12	-	−6.6	−22.6 to 9.5	0.4
≥12	-	- c	-	-
Weight, kg	0.186	0.16	−0.12 to 0.45	0.3
Creatinine Clearance Estimations, mL/min/1.73m2
Modified Schwartze	0.460	0.36	0.33 to 0.40	<0.001
Schwartzf	0.222	0.19	0.14 to 0.23	<0.001
Traube	0.460	0.31	0.28 to 0.34	<0.001
Serum Creatinine, mg/dLf	−0.340d	−29.8	−33.6 to −26.1	<0.001

^aAll covariates were tested using the linear random intercept model. A covariate was considered significant at p-value ≤ 0.05. Time effects, both additive and interaction, were estimated with creatinine clearance only, not weight and age groups as these covariates are expected to remain unchanged during the first 10 days of vancomycin therapy.

^bP-values were ≤ 0.001 for all variables.

^cReference groups were case and age group ≥12 yr.

^dNatural log function of covariate

^eTime effects, both additive and interaction, were observed at p-value ≤0.017.

^fTime effects, both additive and interaction, were not observed.